Characteristics of tertiary lymphoid structures in primary cancers

Jérémy Goc1,2,3, Wolf-Herman Fridman1,2,3, Catherine Sautès-Fridman1,2,3, and Marie-Caroline Dieu-Nosjean1,2,3,*

1The Laboratory of Immune Microenvironment and Tumors; INSERM U872; Cordeliers Research Center; Paris, France; 2University Pierre and Marie Curie; UMR5872; Paris, France; 3University Paris Descartes; UMR5872; Paris, France

Keywords: adaptive immune response, migration, tertiary lymphoid structure, tumor immunology, vasculature

Abbreviations: ADC, adenocarcinoma; APC, antigen-presenting cell; DC, dendritic cell; HEV, high endothelial venule; NSCLC, non-small-cell lung cancer; LT, lymphotoxin; LTi, lymphoid tissue inducer; OS, overall survival; SCC, squamous cell carcinoma; SLO, secondary lymphoid organ; TIL, tumor-infiltrating lymphocyte; TLS, tertiary lymphoid structure; Treg, regulatory T cell

Tumors are sustained by complex networks of interactions between malignant cells, stromal cells and tumor-infiltrating immune cells. These networks differ from patient to patient in terms of nature, composition and organization as well as with regard to the precise localization of tumor-infiltrating cells. Of note, the heterogeneity of the immunological component of the tumor microenvironment, as opposed to its mere abundance, has been shown to influence disease outcome. However, a key question remains: where does the activation of tumor-specific T cells take place? The recently described, tumor-associated lymph node-like entities termed “tertiary lymphoid structures” exhibit a structural organization that is reminiscent of secondary lymphoid organs, and thus may imprint the local immune contexture. Here, we discuss how cancer-associated tertiary lymphoid structures impact on the tumor micro-architecture, immune microenvironment, and ultimately, patient survival.

Introduction

A tumor is a complex network of interacting cellular compartments, comprising malignant cells as well as endothelial, stromal, and immune cells. This so-called “tumor interactome,” which differs from patient to patient, is intimately associated with tumor progression and disease outcome.1

Tumors have been shown to establish an immunosuppressive microenvironment that robustly inhibits, if not completely neutralizes, immune effector cells. This is instrumental for malignant cells to replicate uncontrolled and spread throughout the entire body. Several lines of evidence from mouse and human studies have reported that the immune system can control oncogenesis and tumor progression in spite of such an immunosuppressive pressure, at least under selected circumstances.2-3 More particularly, an association between an abundant infiltration of neoplastic lesions by T cells with improved clinical outcome has been reported in patients affected by multiple types of solid neoplasms.2 However, the mechanisms that govern the shaping of an efficient immune contexture within the tumor remain poorly understood. Moreover, the site(s) at which the activation of tumor-specific effector cells takes place remain(s) unknown. The dogma states that professional antigen-presenting cells (APCs) sample and process antigens within the tumor, then migrate through lymphatic and/or blood vessels to tumor-draining lymph nodes, where they present processed peptides to antigen-specific T and B cells.4 However, an increasing body of evidence has demonstrated that adaptive immune responses that efficiently protect the host against infectious agents can be initiated independently of secondary lymphoid organs (SLOs).5,6 In this setting, antigen presentation appears to take place in ectopic lymph node-like structures that have been named tertiary lymphoid structures (TLSs). TLSs share many structural characteristics with SLOs. In particular, T and B lymphocytes are segregated into 2 distinct and adjacent regions surrounded by specialized blood vessels called high endothelial venules (HEVs), which allows the extravasation of lymphocytes from the blood to the tissue. The T-cell rich area comprises clusters of T cells and mature dendritic cells (DCs). A B-cell follicle is also present, encompassing a ring of naïve B cells around a germinal center that mainly contains B cells, but also T cells, follicular DCs, and macrophages.

The immunological functions of TLSs in cancer have been poorly investigated. Here, we will review novel insights on the impact of cancer-associated TLSs on the micro-architecture of the tumor microenvironment, i.e., its vasculature and global immune contexture, and how the presence of TLSs ultimately affects patient survival.

The Tumor Microenvironment: A Permissive Milieu for Lymphoid Neogenesis?

TLSs have first been described in humans in many non-neoplastic inflammatory contexts, such as autoimmune diseases, viral and bacterial infections, graft rejection, and several idiopathic diseases.5-7 The inducible nature of TLSs was first highlighted by Kratz and colleagues in a transgenic mouse model expressing
lymphotxin (LT)α in pancreatic islets (RIP-LTα model). These authors proposed the term "lymphoid neogenesis" for the process governing the development of TLSs. In contrast to Kratz and colleagues, Moyron-Quiroz et al. observed the genesis of TLSs in a LTα-deficient mice, although these structures appeared less organized than in wild-type animals, primarily consisting of B cells but containing few T cells, no follicular DCs, and no HEVs. These data suggest that LTα participates in the organization of

| Cancers                   | Cellular composition of lymphoid aggregates/TLS                                                                 | Studied cases | Stage of the disease | References                      |
|---------------------------|------------------------------------------------------------------------------------------------------------------|---------------|----------------------|---------------------------------|
| Breast carcinoma          | T cells (including CD4+ T cells, mature DCs)                                                                      | 32 patients   | carcinoma in situ to grade III | Bell et al., 1999              |
|                           | T cells, B cells (GC B cells and naive B cells), FDCs                                                          | 3 patients    | grade II to III       | Coronella et al., 2002          |
|                           | T cells, B cells, PCs, FDCs                                                                                    | 4 patients    | ND                   | Nzula et al., 2003              |
|                           | lymphocytes (hematoxylin counterstaining)                                                                        | 191 patients  | grade II to III       | Gobert et al., 2009             |
|                           | T cells, B cells, HEVs                                                                                           | 146 patients  | grade I to III        | Martinet et al., 2011           |
|                           | T cells (Tfh, CD4+ T cells and few CD8+ T cells), B cells (GC B cells), FDCs                                   | 70 patients   | grade I to III        | Gu-Trantien et al., 2013        |
|                           | T cells, B cells, mature DCs, HEVs                                                                              | 146 patients  | grade I to III        | Martinet et al., 2013           |
| Colorectal carcinoma      | T cells (including CD4+ T cells, memory T cells, few CD8+ T cells), B cells, mature DCs                          | 17 patients   | ND                   | Suzuki et al., 2002             |
|                           | T cells, mature DCs                                                                                              | 40 patients   | grade I to IV         | McMullen et al., 2010           |
|                           | T cells, B cells, FDCs                                                                                           | ND            | ND                   | Bergomas et al., 2011           |
|                           | T cells, B cells (including B cell precursors), FDCs                                                            | 21 patients   | grade 0 to IVA        | Coppola et al., 2011            |
|                           | T cells, B cells, HEVs                                                                                            | 5 patients    | ND                   | Martinet et al., 2011           |
|                           | T cells, B cells, mature DCs                                                                                    | 25 patients   | ND                   | Remark et al., 2013             |
| Colorectal carcinoma liver metastasis | mature DCs                                                                                                        | 70 patients   | ND                   | Miyagawa et al., 2004           |
| Colorectal carcinoma lung metastasis | T cells, B cells, mature DCs                                                                                  | 140 patients  | stage IV              | Remark et al., 2013             |
| Lung carcinoma            | T cells (including CD4+ T cells and few CD8+ T cells), B cells (including GC B cells), mature DCs, FDCs        | 74 patients   | stage I to II         | Dieu-Nosjean et al., 2008       |
|                           | no NK cells                                                                                                      | 86 patients   | stage I to III        | Platonova et al., 2011          |
|                           | T cells (including memory T cells and few naive T cells), mature DCs, HEVs                                     | 15 patients   | stage I to III        | de Chaisemartin et al., 2011    |
|                           | T cells, B cells, HEVs                                                                                            | 5 patients    | ND                   | Martinet et al., 2011           |
| Melanoma                  | memory T cells, mature DCs                                                                                       | 82 patients   | stage IA to IIIA      | Ladányi et al., 2007            |
|                           | T cells (including CD4+ and CD8+ T cells, rare FoxP3+ cells), B cells, mature DCs                               | 21 patients   | stage IV              | Messina et al., 2012            |
|                           | T cells, B cells, HEVs                                                                                            | 18 patients   | ND                   | Martinet et al., 2012           |
|                           | T cells (including CD8+ T cells), B cells (including AID+ GC B cells), mature DCs, FDCs, HEVs                   | 29 patients   | stage IIIB to IV      | Cipponi et al., 2012            |
| Mucosal-Associated Lymphoid Tissue lymphoma | T cells, B cells (including naïve B cells, AID+ GC B cells, marginal zone B cells, malignant B cells), FDCs | 18 patients   | low grade             | Bombardieri et al., 2007        |
|                           | T cells, B cells (including naïve B cells, AID+ GC B cells, marginal zone B cells, malignant B cells), FDCs   | 20 patients   | ND                   | Barone et al., 2008             |
| Ovary carcinoma           | T cells, B cells, HEVs                                                                                            | 18 patients   | ND                   | Martinet et al., 2011           |
| Renal cell carcinoma      | T cells, B cells, mature DCs                                                                                    | 24 patients   | ND                   | Remark et al., 2013             |
| Renal cell carcinoma lung metastasis | T cells, B cells, mature DCs                                                                                    | 52 patients   | stage IV              | Remark et al., 2013             |

Abbreviations: DC, dendritic cell; FDC, follicular DC; GC, germinal center; HEV, high endothelial venule; ND, not determined; TLS, tertiary lymphoid structure.
microenvironments, being more or less permissive to lymphoid neogenesis.

**TLSs and HEVs Crosstalk in a Finely Regulated Manner Within the Tumor Microenvironment**

In many tumors, one of the major hurdles against the efficacy of chemo- and immunotherapy (including anticancer vaccines) is the limited accessibility of immune cells, notably T cells, to the neoplastic lesion. Several mechanisms have been proposed to underlie this phenomenon including the disruption of the architecture and structure of intratumoral blood vessels. The presence of an abnormal vasculature, associated with reduced vessel density, has been reported in multiple cancers, suggesting some sort of disturbance in the neoangiogenetic program. Two main types of blood vessels co-exist in tumors, CD34+ (or CD31+) blood vessels and peripheral node addressin (PNAd)+ HEVs, each of which can differentiate into the other under physiological and pathophysiological conditions. One study suggested that no correlation exists between the densities of blood vessels and that of HEVs in breast carcinoma, suggesting that their developmental programs can proceed independently from each other. 

Strikingly, the intratumoral density of these 2 different types of vessels has an opposite prognostic value in cancer patients. Indeed, high densities of CD34+ (or CD31+) blood vessels are associated with tumor growth and poor clinical outcome in breast, colorectal, and lung cancer patients. These data support a model according to which neoangiogenesis is stimulated by the tumor microenvironment, promoting the formation of vascular emboli and supporting the metastatic spread of neoplastic cells to distant sites. In contrast, the presence of HEVs, which have been observed in melanoma and breast cancer lesions, correlated with long-term patient survival. Moreover, the density of HEVs closely correlated with that of tumor-infiltrating T and B cells, and HEVs were shown to co-localize with cancer-associated TLSs. In lung cancer, the PNAd ligand CD62L, is expressed by most lymphocytes found within TLSs (with the exception of germinal center B cells), but not by lymphocytes present in the other areas of the neoplastic lesion. HEVs are vessels specialized in the extravasation of lymphocytes from the bloodstream to SLOs. Given the strong analogies between SLOs and TLSs, we suggest that HEVs may actively participate in the recruitment of circulating lymphocytes to intratumoral TLSs. Recently, Girard and colleagues demonstrated that DCs play a key role in the regulation of the entry of lymphocyte into SLOs as they maintain a fully mature HEV endothelium in a LTβ receptor-dependent manner. Mature DCs are exclusively detected in the T cell-rich areas of TLSs, adjacent to HEVs. Thus, it is tempting to speculate, but remains to be formally demonstrated, that DCs may regulate lymphocyte trafficking not only in SLOs but also in cancer-associated TLSs.

The mechanisms governing the extravasation of lymphocytes into SLOs are well characterized, and involve 3 main families of molecules: adhesion molecules, chemokines, and integrins. In lung cancer patients, a specific set of adhesion molecules expressed by HEVs have been selectively associated with the presence of TLS: intercellular adhesion molecule (ICAM)2, ICAM3,
vascular cell adhesion molecule 1 (VCAM1), mucosal vascular addressin cell adhesion molecule 1 (MAdCAM1) and PNAd.\textsuperscript{38} In mouse and rat models, intratumoral endothelial cells were shown not to express ICAM1 and VCAM1, as opposed to endothelial cells in distant tissues,\textsuperscript{50,51} in accordance with the downregulation of VCAM1 on the surface of endothelial cells cultured in presence of neoplastic cells.\textsuperscript{52} HEVs expressing ICAM1, VCAM1, MAdCAM1, and PNAd have been also observed in the close proximity of lymphoid aggregates in LT-induced chronic inflammatory lesions.\textsuperscript{8} Moreover, the expression of ICAM2, VCAM1, and PNAd has also been observed in lymphoid aggregates found in non-inflamed human lungs,\textsuperscript{53,54} suggesting that TLSs could represent a favorable microenvironment for the differentiation and maintenance of blood vessels into functional HEVs. ICAM2 is involved in the arrest of circulating T cells along the HEV endothelium of SLOs,\textsuperscript{55} and may have the same function within TLSs. VCAM1 is induced upon inflammation, and contributes to the migration of circulating memory T cells to tissues.\textsuperscript{56} Thus, VCAM1 may represent a key molecule for the recruitment of memory T cells, which are the main T-cell components of lung cancer-associated TLSs.\textsuperscript{38} In contrast, MAdCAM1 is a gut-homing molecule that regulates T-cell migration,\textsuperscript{57} and has not previously shown to contribute to TLS. This suggests that HEVs from lung cancer-associated TLSs exhibit an adhesion molecule profile that differ from that of TLSs surging in non-neoplastic settings.

Altogether, these observations corroborate the hypothesis that TLSs may represent a privileged site for the maturation and maintenance of functional HEVs, unlike the other areas of the tumor microenvironment. TLS-serving HEVs may provide a gateway for the recruitment of circulating T cells into the tumor, and thus represent an interesting target for anticancer immunotherapy (Fig. 1A).

**Chemokines, an Orchestra Conductor of TLS Organization**

The migration of lymphocytes into SLOs is dependent on the expression of various lymphoid chemokines, including CCL19,
CCL21, and CXCL13. The overexpression of these chemokines has been documented in the TLSs of lung and breast carcinoma patients. Moreover, in several murine models, the injection of cancer cells engineered to express either CCL19 and/or CCL21 has been shown to induce a robust infiltration of developing neoplastic lesions by T cells and DCs. This has been associated with a reduction in tumor growth and, at least in some cases, with the induction of a systemic antitumor immune response linked to the control of metastatic dissemination. In human lung cancers, CCL19+ cells are predominantly mature DCs, which are selectively present in TLS. In the lung of mice infected by the influenza virus, the depletion of DCs correlated with a dramatic decrease in TLS density, and the few remaining TLSs were significantly disorganized. The maintenance of TLSs may be partly mediated by DCs via the recruitment of CCR7+ cells, including newly activated DCs and naïve and central-memory T cells, as we observed in lung cancer-associated TLSs. Recently, DCs have also been shown to play a critical role in the induction of lymphangiogenesis within TLSs in a LT- and CCL21-dependent manner. As observed in various inflammatory diseases, lung cancer-associated lymphatic vessels express CCL21. Thus, it is tempting to speculate that CCL21+ lymphatic vessels in the proximity of TLS may represent a major path for immune cells (e.g., activated DCs and central-memory T cells) to reach tumor-draining lymph nodes and establish a systematic protection against metastatic dissemination.

In human lung cancers, CXCL13 was detected on follicular DCs that homed specifically to the germinal centers of B-cell areas within TLSs. Follicular DCs co-localized with a subset of TLS T cells expressing CD4 and chemokine (C-X-C motif) receptor 5 (CXCR5), hence displaying a phenotype of follicular helper T cells. Interestingly, CXCL13+ follicular helper T cells have recently been detected within breast carcinoma-associated TLSs, and their density was associated with long-term patient survival. The density of CXCR5+ follicular B cells also appears to correlate with a favorable clinical outcome among lung cancer patients (Dieu-Nosjean et al., unpublished data) suggesting that the expression of CXCL13 in cancer-associated TLSs may promote the local initiation of a protective humoral immune response through the recruitment of CXCR5+ cells into the germinal center.

CCL17 and CCL22 are also overexpressed in lung cancer-associated TLSs, in agreement with the higher proportion of CCR4+ T cells among TLS-associated T cells as compared with T cells found in other areas of the neoplastic lesion. CCL17 and CCL22 operate by a shared receptor (CCR4), which is expressed by many T-cell subpopulations including T17, T17, T22 T cells, regulatory T cells (Tregs), and effector T cells under inflammatory conditions. Nonetheless, the role of the CCL17/CCL22/CCR4 axis in cancer remains controversial. In some murine models, the intratumoral injection of CCR4 ligands induces tumor regression with a concomitant recruitment of effector T cells whereas in others studies a deleterious effect associated with a strong influx of Tregs has been reported. It should be noted that the prognostic value of tumor-infiltrating Tregs in cancer patients is also a matter of debate. This is likely due to the limited specificity of biomarkers for human Tregs, such as the transcription factor forkhead box P3 (FOXP3), which is also an indicator of the T-cell activation status. Gobert et al. have shown that Tregs are present in the stroma of breast tumors as well as within intratumoral lymphoid aggregates. The migration of Tregs to lymphoid structures is mediated by the CCL22/CCR4 axis. Tregs can be activated by mature DCs, and their high density in lymphoid aggregates is correlated with short-term survival of breast cancer patients. Murine models have illustrated that a high density of intratumoral Tregs correlates with low densities of HEVs, suggesting that HEV neogenesis is inhibited by Tregs. However, in melanoma patients, no correlation was observed between the density of HEVs and that of Tregs. This apparent discrepancy suggest that further investigations are required in order to better define the role of TLS-associated Tregs in oncogenesis and tumor progression.

Interleukin (IL)-16 is also expressed by T and B cells infiltrating lung cancer-associated TLSs. In an asthma model, IL-16 has been shown to operate as a chemoattractant for various CD4+ cells, including CD4+ T cells, DCs and myeloid cells. IL-16 can also prime CD4+ T cells to respond to IL-2 by proliferating, becoming activated and/or differentiating into memory cells. Thus, the role of IL-16 within TLSs may be of particular importance for the functionality of tumor-infiltrating T lymphocytes.

The selective recruitment of immune cells, especially naïve and central-memory CD62L+ T cells, to TLSs led us to hypothesize that TLSs may represent a privileged site for the differentiation and activation of tumor-infiltrating lymphocytes. To obtain further insights into these issues, we have compared the characteristics of the local immune microenvironment with the density of TLSs in patients with lung cancer (Goc et al., manuscript submitted). Patients were stratified into two groups according to the presence of a high or a low density of mature DCs, a cell population that is selectively detected within TLSs and hence is used as a specific TLS marker. Tumor bearing high densities of mature DCs (DCns tumors) contained increased amounts of CD4+ and CD8+ T cells (encompassing naïve, central-memory and effector-memory cells) as well as of activated T cells, as compared with tumors scarcely infiltrated by mature DCs (DClo tumors). Elevated TLS densities also correlated with the overexpression as well as the coordination of genes linked to T1p polarization, cytotoxicity, activation, and immune effector functions. In contrast, genes involved in T1p polarization, inflammation, immunosuppression, and angiogenesis were not differentially expressed by DCns and DClo tumors. These data indicate that high TLS densities are associated with a specific intratumoral contexture that is characterized by the coordination of adaptive immune responses.
cellular immune responses (Fig. 1B). This suggests that TLS might directly impact on the intratumoral immune contexture in lung cancer patients. Similar findings have been reported in lung metastases of colorectal carcinoma but not renal cell carcinoma, in agreement with the differential density of TLSs found in these cancer types. Of note, the protective effects of a T$_{H}1$ and cytotoxic immune signature have been widely demonstrated in mice, and correlate with a favorable disease outcome in patients affected by most solid cancers (exception made for renal cell carcinoma and ocular melanoma). However, the possibility that such immune signature may be associated with the density of TLSs has never been reported.

One of the remaining key questions is whether TLSs are directly involved in the induction of antitumor immune responses, or, vice versa, whether they relay locally an intense immune reaction initiated in SLOs. Several lines of evidence support the former possibility. First, it has been demonstrated that antitumor immune responses can develop within neoplastic lesions in mice lacking SLOs. This demonstrates that effective T-cell priming can be achieved within intratumoral TLSs independently of SLOs. Second, the presence of TLSs has been correlated with the generation of tumor-specific T cells, suggesting that TLSs could act as a functional site for the induction of protective antitumor immunity. Similar findings have also been obtained in models of infectious diseases, indicating that TLSs may represent an active site for the induction of adaptive immune responses in multiple settings.

In summary, it seems that the presence of a favorable (or at least a permissive) tumor microenvironment allows for the creation of TLSs, which is critical for the local coordination and polarization of protective antitumor immune responses.

**TLS as a Novel Biomarker in Cancer**

The majority of prognostic studies has highlighted a positive impact of intratumoral T cells on the survival of patients affected by solid tumors. The high reproducibility of these data strongly support the idea that one should take into account immune criteria for the prognostic staging of neoplastic lesions. Several studies have indeed reported a favorable clinical outcome for lung cancers patients whose neoplastic lesions contain a high density of CD8$^{+}$ T cells (Refs. 86,87 and Goc et al., submitted manuscript). Moreover, a high density of mature DCs (a specific marker of TLS) has been correlated with the long-term survival of patients affected by early-stage, advanced and metastatic lung cancer (Refs. 37,40 and Goc et al., submitted manuscript).

Thus the survival of lung cancer patients appears to be positively influenced by the abundance of tumor-infiltrating mature DCs and CD8$^{+}$ T cells. This raises the question of evaluating the clinical impact of these tumor-infiltrating cells in combination. The stratification of lung cancer patients (at all disease stages) according to low or high densities of intratumoral mature DCs and CD8$^{+}$ T cells (DC$^{lo}$/CD8$^{hi}$, DC$^{hi}$/CD8$^{lo}$, DC$^{hi}$/CD8$^{hi}$, and DC$^{lo}$/CD8$^{lo}$ patients) provided several interesting hints (Goc et al., submitted manuscript). First, patients with a high density of mature DCs, regardless of the density of CD8$^{+}$ T cells (DC$^{lo}$/CD8$^{lo}$ and DC$^{lo}$/CD8$^{hi}$ groups), were at lower risk of death than their DC$^{hi}$ counterparts, indicating that elevated amounts of intratumoral mature DCs are sufficient to favorably impact on clinical outcome. This said, it should be noted that most of DC$^{hi}$ tumors are also highly infiltrated by CD8$^{+}$ T cells. In this context, the scarcity of DC$^{lo}$/CD8$^{lo}$ tumors suggests a causal link between the presence of TLSs and that of tumor-infiltrating CD8$^{+}$ T cells. This observation further supports the hypothesis that intratumoral TLSs represent an active site for the recruitment, activation, proliferation, and priming of tumor-infiltrating T cells. Second, patients with low intratumoral amounts of both mature DCs and CD8$^{+}$ T cells (DC$^{lo}$/CD8$^{lo}$ group) turned out to have a poor clinical outcome as compared with the three other groups of patients (DC$^{lo}$/CD8$^{hi}$, DC$^{hi}$/CD8$^{lo}$, and DC$^{hi}$/CD8$^{hi}$ patients). This demonstrates that the DC/CD8 score allows for the identification of a subgroup of patients with a very high risk of death. Finally, patients with a high density of tumor-infiltrating CD8$^{+}$ T cells but a low density of mature DCs (DC$^{lo}$/CD8$^{hi}$ individuals) exhibited an intermediate risk of death. These data suggest that a high density of tumor-infiltrating CD8$^{+}$ T cells in the absence of a robust tumor infiltration by mature DCs is not sufficient to predict favorable disease outcome among lung cancer patients. The presence of mature DCs appears therefore to be required to license the positive prognostic value of tumor-infiltrating CD8$^{+}$ T cells. In absence of TLSs, high density of intratumoral CD8$^{+}$ T cells may be less efficient in maintaining long-term protective antitumor immunity. Similar results have been obtained with regard to tumor-infiltrating B cells and CD8$^{+}$ T cells in ovarian cancer patients.

The presence of TLSs may imprint the behavior of tumor-infiltrating CD8$^{+}$ T cells. This assumption is in agreement with the involvement of TLSs in the local activation of CD8$^{+}$ T cells, which has been demonstrated in different murine models. Several mechanisms might explain the survival benefit related to elevated densities of cancer-associated TLSs. Mature DCs, which may have engulfed a large spectrum of tumor-associated antigens (TAA$s$), are very efficient at presenting processed peptides to antigen-specific T cells (Fig. 1B). In addition, the recruitment of naive T cells into TLSs is highly favorable for the continuous activation of new T-cell clones specific for newly arising TAA$s$ (Fig. 1C). Moreover, the local stimulation of intratumoral T cells by mature DCs might potentiate their effector functions and limit their sensitivity to anergy and/or exhaustion. Finally, CD4$^{+}$ T cells, which represent the major T-cell subset of TLSs, could deliver important help signals to CD8$^{+}$ T cells. In a murine model of pancreatic cancer, it has been illustrated that the “help” coming from CD4$^{+}$ T cells can also limit the induction of tolerance and the depletion of CD8$^{+}$ T cells, promote the survival of effector-memory T cells and optimize their effector activity.

It should be noted that the improved prognosis associated with a high density of tumor-infiltrating mature DCs was observed among lung cancer patients who underwent surgical tumor resection, and hence who were deprived of all tumor-infiltrating immune cells. This suggests that the prognostic value of intratumoral mature DCs is most likely related to the development of systemic antitumor immunity, in turn...
originating from local adaptive immune responses orchestrated within TLSs. As such, the presence of lymphatic vessels close to TLSs may participate in the emigration of some immune cell populations, including central-memory T cells, to tumor-draining lymph nodes, a key pathway for the establishment of robust systemic immunity against micro-metastasis (Fig. 1D).

Conclusions

The presence of TLSs has been documented in many solid tumors, in both mice and humans. Interestingly, TLSs manifest a huge variability in terms of density and cellular organization, indicating that the nature of tumor microenvironment is critical for lymphoid neogenesis. In this context, one of the challenges for the future is to precisely determine the conditions that provide an optimal environment for the induction and maintenance of cancer-associated TLSs.

In addition, the presence of particular vessels, namely, HEVs, around TLSs strongly suggests that this microenvironment represents an ideal gateway for the entry of circulating lymphocytes into TLSs, a step that is critical for the initiation of adaptive immune responses, as demonstrated in SLOs. Moreover, TLSs can imprint the local immune contexture, hence influencing disease outcome in cancer patients. Thus, the density of CD8+ T cells predicts long-term survival among lung cancer patients only in presence of TLS-associated DCs. These data need to be confirmed in patients affected by other solid tumors. Nonetheless, the presence of TLSs provides per se a survival benefit to cancer patients. We speculate that lymphoid neogenesis might represent an interesting target for eliciting and/or boosting antitumor immunity in cancer patients. Moreover, TLSs may be used in the future as a novel biomarker for the identification of cancer patients with a high risk of relapse. A deeper comprehension of the cellular and molecular mechanisms whereby TLSs confer long-term protection to cancer patients is essential to develop efficient strategies for their therapeutic manipulation.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We are grateful to Pr. J. Bienenstock and Dr. J.-L. Teillaud for critical reading of the manuscript. We thank Dr. Helen Angell for English critics of this manuscript.

References

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013

2. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumors: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3345

3. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:503-7; PMID:18026085; http://dx.doi.org/10.1038/nature06309

4. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/nature10767

5. Drayton DL, Liao S, Mounet RH, Ruddle NH. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006; 7:344-53; PMID:16595197; http://dx.doi.org/10.1038/nii.2006.73

6. Nery K, Perus F, GeurtzvanKessel CH, Hammad H, Lambrecht BN. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol 2012; 33:297-305; PMID:22622061; http://dx.doi.org/10.1016/j.it.2012.04.006

7. Aloni F, Pajol-Borre R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006; 6:205-17; PMID:16498451; http://dx.doi.org/10.1038/nri.2006.78

8. Kratz A, Campos-Neto A, Hanson MS, Ruddle NH. Chronic inflammation caused by lymphotixin is lymphoid neogenesis. J Exp Med 1996; 183:614-72; PMID:8666094; http://dx.doi.org/10.1084/jem.183.4.1461

9. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, Goodrich S, Woodland DL, Lund FE, Randall TD. Role of inducible banchusAssociated lymphoid tissue (BALT) in respiratory immunity. Nat Med 2004; 10:927-34; PMID:15311275; http://dx.doi.org/10.1038/nm1091

10. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, Goodrich S, Woodland DL, Lund FE, Randall TD. Role of inducible banchusAssociated lymphoid tissue (BALT) in respiratory immunity. Nat Med 2004; 10:927-34; PMID:15311275; http://dx.doi.org/10.1038/nm1091

11. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, Goodrich S, Woodland DL, Lund FE, Randall TD. Role of inducible banchusAssociated lymphoid tissue (BALT) in respiratory immunity. Nat Med 2004; 10:927-34; PMID:15311275; http://dx.doi.org/10.1038/nm1091
26. Coroellna JA, Spier C, Welch M, Trevor KT, Snoeck AT, Villar H, Hersh EM. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 2002; 168:1926-34; PMID:12065600; http://dx.doi.org/10.4049/jimmunol.168.3.1926.

27. Gu-Trantier C, Loi S, Garaud S, Equeur C, Libin M, de Wind A, Ravot M, Le Buanec H, Sibille C, Manfouo-Foutsop G, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123:2873-92; PMID:23778140; http://dx.doi.org/10.1172/JCI74728.

28. Naula S, Gowing JJ, Stott DI. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 2003; 63:3275-80; PMID:12808695.

29. Gobert M, Treilleux L, Bendriss-Vermare N, Bachelot T, Martinet L, Filleron T, Le Guellec S, Rochaix P, Martinet L, Filleron T, Le Guellec S, Rochaix P, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girardo I, Girard
62. Yang S-C, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Arianza K, Kuo BY, Gardner B, Batra RK, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic anti-tumor responses and confers tumor immunity. Clin Cancer Res 2004; 10:2891-901; PMID:15102698; http://dx.doi.org/10.1158/1078-0432.CCR-03-0380

63. Yang S-C, Batra RK, Hillinger S, Reckamp KL, Strierer RM, Dubinett SM, Sharma S. Intraperitoneal administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2006; 66:3205-13; PMID:16540672; http://dx.doi.org/10.1158/0008-5472.CAN-05-3619

64. Yousefi N, Halto SM, Stephens AL, Ciavarra RP. Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotropic model of prostate cancer. Cancer Microenviroment 2009; 2:59-67; PMID:19418243; http://dx.doi.org/10.1016/j.jcm.2009.07-002-a

65. GeurtsvanKessel CH, Willart MA, Bergen IM, van Hendriks R, Rimmelzwaan GF, Lambrecht BN. Targeted knock down of CCL22 and CCL17 by adenoviral vector. Cancer Res 2008; 68:4957-67; PMID:18560101; http://dx.doi.org/10.1158/0008-5472.CAN-07-3851

66. Halle S, Dujardin HC, Bakovic N, Fleige H, Danzer H, Willenzen S, Suezer Y, Hamerling G, Garbi N, Sutter G, et al. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med 2009; 206:2539-601; PMID:19917776; http://dx.doi.org/10.1084/jem.20090472

67. Munir LR, Pacer ME, Lira SA, Furtado GC. A critical role for dendritic cells in the formation of lymphatic vessels within tertiary lymphoid structures. J Immunol 2011; 187:828-34; PMID:21660655; http://dx.doi.org/10.4049/jimmunol.1004433

68. Zielinski CE, Corri D, Mele P, Finto D, Lanzavecchia A, Sallusto F. Dissecting the human immune memory for pathogens. Immunol Rev 2011; 240:40-51; PMID:2149085; http://dx.doi.org/10.1111/j.1600-065X.2010.01000.x

69. Inoue H, Iga M, Xin M, Asahi S, Nakamura T, Zielinski CE, Corti D, Mele F, Pinto D, Lanzavecchia A, Sallusto F. Immunological tumor microenvironment inhibits tumor growth and metastasis in an orthotropic model of prostate cancer. Cancer Microenviroment 2009; 2:59-67; PMID:19418243; http://dx.doi.org/10.1016/j.jcm.2009.07-002-a

70. Kang S, Xie J, Ma S, Liao W, Zhang J, Luo R. Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets. Immunobiology 2010; 215:153-62; PMID:19450895; http://dx.doi.org/10.1016/j.imbio.2009.03.001

71. Okada N, Sasaki A, Niwa M, Okada Y, Hatanaka Y, Tani Y, Mizuguchi H, Nakagawa S, Fujita T, Yamamoto A. Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector. Cancer Gene Ther 2006; 13:393-405; PMID:16224496; http://dx.doi.org/10.1038/sj.ct.7700993

72. Mizukami Y, Kono K, Kawaguchi Y, Aikahi I, Kamimura K, Sugai H, Fujii H. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 2008; 122:2286-93; PMID:18224687; http://dx.doi.org/10.1002/ijc.23395

73. Qin X-J, Shi H-Z, Deng J-M, Liang Q-L, Jiang J, Ye Z-J. CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res 2009; 15:2321-7; PMID:19318474; http://dx.doi.org/10.1158/1078-0432.CCR-08-2641

74. Hindley JP, Jones E, Smart K, Bridgehan H, Lauder SN, Ondondo B, Curtin S, Ladell K, Wynn KK, Withers D, et al. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res 2012; 72:5473-82; PMID:22992270; http://dx.doi.org/10.1158/0008-5472.CAN-12-1912

75. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the thera peutic activity of regulatory T cells against established melanoma. J Exp Med 2008; 205:2125-38; PMID:18725922; http://dx.doi.org/10.1084/jem.20080099

76. Kaser A, Dunzendorfer S, Offner FA, Ludwiczek O, Enrich B, Koch RO, Cnirkshank WW, Wiedermann CJ, Tilg HB. B lymphocyte-derived IL-16 attracts T cells and is maintained by dendritic cells and Th cells. J Immunol 2000; 164:2474-80; PMID:10946273

77. Krug N, Cnirkshank WW, Tischmier T, Enrich M, Vahle B, Hoefld MM, Center DM, Fabel H. Interleukin-16 and T-cell chemotaxtract activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma. Am J Respir Crit Care Med 2000; 162:105-11; PMID:10903228; http://dx.doi.org/10.1164/ajrccm.162.1.9908055

78. Parada NA, Center DM, Korotfeld H, Rodrigue WL, Cook J, Vallen M, Cnirkshank WW. Synergistic activation of CD4+ T cells by IL-16 and IL-2. J Immunol 1998; 160:215-20; PMID:9498748

79. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting; integrating immunity's roles in cancer suppression and promotion. Science 2002; 296:3015-20; PMID:12063444; http://dx.doi.org/10.1126/science.1203486

80. Kirk CJ, Hartigan-O'Connr D, Mulé JJ. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 2001; 61:8794-802; PMID:11751401

81. Schrama D, thor Straten P, Fischer WH, McMellon AD, Bröcker EB, Reisfeld RA, Becker JC. Targeting of lymphotixin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 2001; 14:111-21; PMID:11239444; http://dx.doi.org/10.1016/S1074-7613(01)00094-2

82. Senovilla L, Vecchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:3323-43; PMID:23243596; http://dx.doi.org/10.4161/onci.22009

83. Schrama D, Thor Straten P, MacMillan WH, De, Eu Y-X, Engellund VH. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 2010; 207:1791-804; PMID:20660615; http://dx.doi.org/10.1084/jem.20092454

84. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12:492-9; PMID:21739672; http://dx.doi.org/10.1038/ni.2035

85. Aubert RD, Kamphorst AO, Sarkar S, Veys V, Ha SJ, Barber DL, Ye L, Sharpe AH, Freeman GJ, Ahmed R. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc Natl Acad Sci U S A 2011; 108:21182-7; PMID:22160724; http://dx.doi.org/10.1073/pnas.1114850109

86. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytokine-lytic function of CD8+ T lymphocytes. Cancer Res 2010; 70:8368-77; PMID:20940398; http://dx.doi.org/10.1158/0008-5472.CAN-10-1322

www.landesbioscience.com Oncoimmunology e26836-9